BACK TO THE LAB: Eli Lilly and Co. will undertake another late-stage study of one of its experimental Alzheimer’s drugs next year, sending shares of the pharmaceutical company downward with a lengthy road ahead. However, the announcement shows that Lilly is confident of success despite previous shortfalls for solanezumab.
MIXED SUCCESS: Lilly said in August the intravenous treatment failed to slow memory decline in two late-stage studies of about 1,000 patients each. But scientists saw a statistically significant slowing when they combined trial data. They also saw it when they examined a subgroup of patients with mild cases of Alzheimer’s disease.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.